Sight Sciences (SGHT) Q2 2025 Earnings Call August 07, 2025 04:30 PM ET Speaker0Good day, and thank you for standing by. Welcome to the SITE Sciences Second Quarter twenty twenty five Earnings Results Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you'll need to press 11 on your telephone.You'll then hear an automated message advising your hand is raised. To withdr ...

Investor Presentation Sight Sciences August 2025 Forward-Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements are subject to considerable risks and uncertainties. The Company intends such forward- looking statements to be covered by the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ____________ Commission File Number: 001-40587 SIGHT SCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 80-0625749 (State or other jurisdict ...

Exhibit 99.1 Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance MENLO PARK, Calif., August 7, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives,today reported financial results for the second quarter ended June 30, 2025, and raised its revenue guid ...

MENLO PARK, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today reported financial results for the second quarter ended June 30, 2025, and raised its revenue guidance while reaffirming its adjusted operating expense guidance, both for full year 2025. Recent Financial and Busines ...

MENLO PARK, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, today announced it will report financial results for the second quarter ended June 30, 2025, after the market close on Thursday, August 7, 2025. The Company’s management will discuss the results during a conference call beginning at 1: ...

Summary of the Conference Call Company and Industry Overview - The conference call involved **Site Sciences**, focusing on the **surgical glaucoma** and **dry eye** treatment markets, particularly the **minimally invasive glaucoma surgery (MIGS)** segment and the **TearCare** product for dry eye treatment [1][2][18]. Key Points on Surgical Glaucoma - **First Quarter Performance**: Surgical glaucoma revenue was initially guided to decline by 10-15% year-over-year but only decreased by 6%, indicating better-than-expected performance [2][26]. - **MIGS Environment**: The company is navigating a dynamic MIGS environment due to new restrictions limiting the combination of multiple MIGS procedures during cataract surgery, which has led to a decline in claims for these devices [3][4]. - **Product Performance**: Both **Omni** and **Scion** devices are performing slightly better than expected, with Omni's strong clinical efficacy and surgeon preference contributing to its market share [4][10]. - **Market Dynamics**: The transition to a one MIGS world is ongoing, with Omni positioned well due to its comprehensive functionality, allowing it to address multiple points of resistance in the outflow pathway [6][7]. - **Claims Data**: The volume of visits involving multiple MIGS procedures has dropped from 15% to 5%, indicating a significant shift in the market [11][12]. - **Long-term Growth Potential**: The market for MIGS is not fully penetrated, with significant opportunities in the combination cataract segment, as many patients undergoing cataract surgery are not receiving MIGS [18][19]. Key Points on Dry Eye Treatment - **TearCare Opportunity**: The company is focused on pioneering a new category of interventional dry eye treatment, addressing the underlying causes of dry eye disease, particularly obstructed meibomian glands [42][45]. - **Payer Discussions**: Productive conversations with payers are ongoing, with expectations for coverage policies and payment decisions to begin in 2025 [45][46]. - **Market Size**: There are over 19 million diagnosed patients with dry eye disease in the U.S., with a significant portion suffering from moderate to severe conditions, representing a large market opportunity [55][57]. - **Procedure Volume Potential**: The company estimates a potential for 7-8 million patients to undergo one or two procedures annually, depending on reimbursement rates [56][57]. - **Existing Infrastructure**: Site Sciences has a lean but experienced sales team ready to ramp up once reimbursement decisions are made, with over 1,500 trained smart hubs in place [49][50]. Additional Insights - **Competitive Landscape**: The introduction of new competitors, such as the Via 360 device, is acknowledged, but the company remains confident in the Omni product line and its ongoing innovations [31][34]. - **Market Education**: There is a need for continued education among surgeons regarding the importance of MIGS in the treatment paradigm to increase adoption rates [25][24]. - **Long-term Confidence**: The company expresses confidence in the long-term growth of both the MIGS and dry eye markets, emphasizing the importance of addressing unmet patient needs [20][21].

Core Insights - Sight Sciences, Inc. is an eyecare technology company focused on developing innovative interventional technologies to transform care and improve patients' lives [1][3] - The company will present at the Stifel 2025 Virtual Ophthalmology Forum on May 27, 2025 [2] Company Overview - Sight Sciences specializes in minimally invasive or non-invasive solutions targeting prevalent eye diseases, aiming to enhance patient care and replace outdated treatment methods [3] - The OMNI® Surgical System and OMNI® Edge Surgical System are implant-free technologies for glaucoma surgery, indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma [3] - The SION® Surgical System is a bladeless device for excising trabecular meshwork in ophthalmic procedures [3] - The TearCare® System is cleared for localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland disease, addressing the leading cause of dry eye [3]

Financial Performance - For the quarter ended March 2025, Sight Sciences, Inc. reported revenue of $17.51 million, a decrease of 9.1% year-over-year [1] - The earnings per share (EPS) was -$0.28, an improvement from -$0.33 in the same quarter last year [1] - The reported revenue exceeded the Zacks Consensus Estimate of $16.53 million by 5.95% [1] - The company delivered an EPS surprise of 3.45%, with the consensus EPS estimate being -$0.29 [1] Key Metrics - Revenue from Dry Eye was $0.39 million, surpassing the average estimate of $0.23 million, but reflecting a year-over-year decline of 60.9% [4] - Revenue from Surgical Glaucoma was $17.11 million, exceeding the estimated $16.23 million, but down 6.3% compared to the previous year [4] - Gross Profit for Dry Eye was $0.28 million, significantly higher than the two-analyst average estimate of $0.07 million [4] - Gross Profit for Surgical Glaucoma was $14.82 million, also above the estimated $14.09 million by two analysts [4] Stock Performance - Shares of Sight Sciences have returned +21.7% over the past month, outperforming the Zacks S&P 500 composite's +11.3% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Company Performance - Sight Sciences, Inc. reported a quarterly loss of $0.28 per share, which was better than the Zacks Consensus Estimate of a loss of $0.29, and an improvement from a loss of $0.33 per share a year ago, indicating an earnings surprise of 3.45% [1] - The company posted revenues of $17.51 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 5.95%, although this represents a decline from year-ago revenues of $19.27 million [2] - Over the last four quarters, Sight Sciences has exceeded consensus EPS estimates three times and has topped consensus revenue estimates three times as well [2] Stock Performance - Sight Sciences shares have declined approximately 21.4% since the beginning of the year, contrasting with the S&P 500's decline of 4.3% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.30 on revenues of $18.38 million, and for the current fiscal year, it is -$1.15 on revenues of $72.02 million [7] Industry Outlook - The Medical - Instruments industry, to which Sight Sciences belongs, is currently ranked in the top 28% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]